Added to YB: 2025-11-17
Pitch date: 2025-11-14
NVO [bullish]
Novo Nordisk A/S
+1.39%
current return
Author Info
HatedMoats identifies hated moats. I buy companies when the market panics. Contrarian investor focused on quality, value & long-term growth. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 312.05
Price Target
N/A
Dividend
3.63%
EV/EBITDA
8.96
P/E
13.76
EV/Sales
4.74
Sector
Pharmaceuticals
Category
value
Novo Nordisk: Q3 Review & How is the company actually doing this year?
NVO (earnings): Strong 15% CER sales growth to DKK 230B driven by GLP-1 demand, but margins hit by DKK 9B restructuring charges in Q3. Ex-restructuring, EBIT +21% CER. Wegovy +54% CER, obesity 59% market share. New CEO kitchen-sinking 2025 to reset 2026 expectations lower. Pipeline expanding with oral semaglutide, MASH approval. Risks: US compounding, Lilly competition, capacity constraints. Undervalued moat remains intact.
Read full article (7 min)